The identification of the HUB genes via the predicted interactions, also known as the interactome (Li, Sahni & Yi, 2016), is a powerful system-level approach that has been used in a variety of contexts to generate hypotheses and shape future research, including lung adenocarcinoma (Selamat et al., 2012), and prostate cancer (Song et al., 2019). The gene discussed is ELAVL2; the disease is prostate carcinoma.